澳大利亚23价肺炎球菌多糖疫苗接种项目的回顾性成本效果分析
该研究采用多队列马尔可夫模型,从医疗系统角度回顾性评估2005至2015年澳大利亚65岁以上成人PPV23免疫规划的成本效果。结果显示,11年间PPV23 prevented 771例住院和99例死亡,但估计的IPD病例和死亡预防数下降超过50%;结论认为PPV23项目成本效果随时间恶化,除非对非侵袭性肺炎提供保护或谈判低价,否则不太可能具有成本效果。
要点
- 2005-2015年PPV23累计估计预防771例IPD住院和99例死亡。
- 估计的IPD死亡预防数从2005年12.9例降至2015年6.1例。
核心结论
- 澳大利亚老年人PPV23项目的成本效果估计随时间恶化,除非PPV23对非侵袭性肺炎球菌肺炎提供保护或谈判获得低价,否则不太可能具有成本效果。
- 关键政策优先事项应是审查PPV23在澳大利亚的未来使用,在某些高危人群中可能更具成本效果。
研究设计与样本
- 采用多队列马尔可夫模型,周期长度一年,回顾性评估2005至2015年PPV23免疫规划的成本效果。
- 分析从医疗系统角度进行,成本和QALY按每年5%贴现。
- 分别计算2005至2015年每年提供的PPV23剂量与不接种相比的ICER。
- 使用确定性和概率敏感性分析探索参数不确定性。
主要发现
- 估计2005至2015年11年间提供的PPV23剂量预防了771例侵袭性肺炎球菌疾病(IPD)住院和99例死亡。
- 估计PPV23预防的IPD病例和死亡在该期间下降超过50%,例如2005年提供的剂量对应12.9例死亡预防,2015年对应6.1例。
- 下降可能由婴儿PCV项目的群体效应驱动。
- 2005至2015年期间与不接种相比的估计ICER约为224,000澳元/QALY获得。
- 按年检查,ICER从2005年140,000澳元/QALY恶化至2011年238,000澳元/QALY,至2015年286,000澳元/QALY。
临床怎么用
- 原文结论提示应审查PPV23在澳大利亚的未来使用,某些高危人群可能更具成本效果。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Australian infant pneumococcal vaccination program was funded in 2005 using the 7-valent pneumococcal conjugate vaccine (PCV7) and the 13-valent conjugate vaccine (PCV13) in 2011. The PCV7 and PCV13 programs resulted in herd immunity effects across all age-groups, including older adults. Coincident with the introduction of the PCV7 program in 2005, 23-valent pneumococcal polysaccharide vaccine (PPV23) was funded for all Australian adults aged over 65 years. METHODS: A multi-cohort Markov model with a cycle length of one year was developed to retrospectively evaluate the cost-effectiveness of the PPV23 immunisation program from 2005 to 2015. The analysis was performed from the healthcare system perspective with costs and quality-adjusted life years discounted at 5% annually. The incremental cost-effectiveness ratio (ICER) for PPV23 doses provided from 2005 to 2015 was calculated separately for each year when compared to no vaccination. Parameter uncertainty was explored using deterministic and probabilistic sensitivity analysis. RESULTS: It was estimated that PPV23 doses given out over the 11-year period from 2005 to 2015 prevented 771 hospitalisations and 99 deaths from invasive pneumococcal disease (IPD). However, the estimated IPD cases and deaths prevented by PPV23 declined by more than 50% over this period (e.g. from 12.9 deaths for doses given out in 2005 to 6.1 in 2015), likely driven by herd effects from infant PCV programs. The estimated ICER over the period 2005 to 2015 was approximately A$224,000/QALY gained compared to no vaccination. When examined per year, the ICER for each individual year worsened from $140,000/QALY in 2005 to $238,000/QALY in 2011 to $286,000/QALY in 2015. CONCLUSION: The cost-effectiveness of the PPV23 program in older Australians was estimated to have worsened over time. It is unlikely to have been cost-effective, unless PPV23 provided protection against non-invasive pneumococcal pneumonia and/or a low vaccine price was negotiated. A key policy priority should be to review of the future use of PPV23 in Australia, which is likely to be more cost-effective in certain high-risk groups.
引用
- Chen C, Beutels P, Wood J, et al. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. Vaccine. 2018. PMID: 30213457. doi:10.1016/j.vaccine.2018.08.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。